Advertisement

Study Finds Treatment Delays for Patients With Breast Cancer Early in the COVID-19 Pandemic


Advertisement
Get Permission

The results of an online questionnaire of 609 breast cancer survivors in the United States suggest that nearly half of patients experienced delays in care during the early weeks of the COVID-19 pandemic. The study was published by Papautsky et al in the journal Breast Cancer Research and Treatment.

“The motivation for the study came from widespread reports of cancer care being delayed or procedures being canceled in the beginning of the pandemic, and we wanted to get a better handle on what was happening,” said study author Elizabeth Papautsky, PhD, Assistant Professor of Biomedical and Health Information Sciences at the University of Illinois at Chicago College of Applied Health Sciences.

Study Methods

Dr. Papautsky and coauthor Tamara Hamlish, PhD, a research scientist in the cancer survivorship program at the University of Illinois Cancer Center, developed a questionnaire that asked about care delays. They distributed the questionnaire to U.S. breast cancer survivor groups on social media and via e-mail. They used the National Cancer Institute's definition of a cancer survivor, which includes anyone who has received a diagnosis of cancer.

Between April 2 and April 27, 2020, the researchers received 609 responses.

The questionnaire sought to identify what kinds of care were delayed: chemotherapy, radiation, cancer surgery, hormonal treatment, or routine follow-up appointments. There also were demographic questions on race and age, as well as stage of cancer.

Sixty-three percent of respondents were currently receiving cancer care, and the average age of the respondents was 47. Among the respondents, 78% identified as White; 17% as Black; and 3% as Asian.

“Overall, we see that there is a serious gap in disaster preparedness when it comes to providing critical and often time-sensitive care for [patients] with breast cancer.”
— Tamara Hamlish, PhD

Tweet this quote

Questionnaire Results

The researchers found that 44% of the respondents reported a delay in care. The most commonly reported delay was for routine follow-up visits. Respondents reported the highest rate of delays in routine follow-up appointments (79%), breast reconstruction surgery (66%), diagnostic imaging (60%), and laboratory testing (50%). Approximately 30% of respondents reported delays in hospital- or clinic-based cancer therapies, including radiation (30%), infusion therapies (32%), and surgical tumor removal (26%).

“We expected the usual racial difference we see in health care, with Black patients being disproportionately affected, but our results showed that patients were universally affected by COVID[-19] in terms of delays in breast cancer care, likely because in those early weeks, hospitals and health-care facilities were postponing visits and procedures across the board as they took on the growing burden of dealing with COVID-19,” explained Dr. Hamlish.

“We were surprised to see that younger women were more likely to experience delays, and we think that has to do with cancellations of hormone therapy for ovarian suppression that is given to women with certain types of breast cancer, and those women tend to be younger in general,” added Dr. Papautsky.

In the study, the authors found that age was the only demographic variable that had an impact on the likelihood of a delay in care.

The questionnaire also had a section for general comments. Many respondents said that their treatment may have been modified instead of totally cancelled, the researchers said. One example they noted was that hormone therapies may have been spaced out more to reduce the number of clinic visits.

“Overall, we see that there is a serious gap in disaster preparedness when it comes to providing critical and often time-sensitive care for [patients] with breast cancer,” concluded Dr. Hamlish.

Disclosure: For full disclosures of the study authors, visit springer.com.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Advertisement

Advertisement



Advertisement